Global Radiopharmaceutical Solutions 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR052504380

Publication Date:

May 8, 2025

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Radiopharmaceutical Solutions market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Radiopharmaceutical Solutions market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radiopharmaceutical Solutions market size and forecasts, in consumption value ($ Million), 2020-2031
Global Radiopharmaceutical Solutions market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Radiopharmaceutical Solutions market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Radiopharmaceutical Solutions market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Radiopharmaceutical Solutions
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Radiopharmaceutical Solutions market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include IBA, GE Healthcare, Actinium Pharmaceuticals, Alseres Pharmaceuticals, Cardinal Health, Jubilant Pharma, Central Research Laboratories, Cyclomedica, Bracco, Eckert & Ziegler Radiopharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Radiopharmaceutical Solutions market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Oral Tracking
Vein Tracking
麻豆原创 segment by Application
Hospitals
Health Systems
Others
麻豆原创 segment by players, this report covers
IBA
GE Healthcare
Actinium Pharmaceuticals
Alseres Pharmaceuticals
Cardinal Health
Jubilant Pharma
Central Research Laboratories
Cyclomedica
Bracco
Eckert & Ziegler Radiopharma
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Radiopharmaceutical Solutions product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Radiopharmaceutical Solutions, with revenue, gross margin, and global market share of Radiopharmaceutical Solutions from 2020 to 2025.
Chapter 3, the Radiopharmaceutical Solutions competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Radiopharmaceutical Solutions market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Radiopharmaceutical Solutions.
Chapter 13, to describe Radiopharmaceutical Solutions research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Radiopharmaceutical Solutions by Type
1.3.1 Overview: Global Radiopharmaceutical Solutions 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Radiopharmaceutical Solutions Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Oral Tracking
1.3.4 Vein Tracking
1.4 Global Radiopharmaceutical Solutions 麻豆原创 by Application
1.4.1 Overview: Global Radiopharmaceutical Solutions 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospitals
1.4.3 Health Systems
1.4.4 Others
1.5 Global Radiopharmaceutical Solutions 麻豆原创 Size & Forecast
1.6 Global Radiopharmaceutical Solutions 麻豆原创 Size and Forecast by Region
1.6.1 Global Radiopharmaceutical Solutions 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Radiopharmaceutical Solutions 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Radiopharmaceutical Solutions 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Radiopharmaceutical Solutions 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Radiopharmaceutical Solutions 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Radiopharmaceutical Solutions 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Radiopharmaceutical Solutions 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 IBA
2.1.1 IBA Details
2.1.2 IBA Major Business
2.1.3 IBA Radiopharmaceutical Solutions Product and Solutions
2.1.4 IBA Radiopharmaceutical Solutions Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 IBA Recent Developments and Future Plans
2.2 GE Healthcare
2.2.1 GE Healthcare Details
2.2.2 GE Healthcare Major Business
2.2.3 GE Healthcare Radiopharmaceutical Solutions Product and Solutions
2.2.4 GE Healthcare Radiopharmaceutical Solutions Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 GE Healthcare Recent Developments and Future Plans
2.3 Actinium Pharmaceuticals
2.3.1 Actinium Pharmaceuticals Details
2.3.2 Actinium Pharmaceuticals Major Business
2.3.3 Actinium Pharmaceuticals Radiopharmaceutical Solutions Product and Solutions
2.3.4 Actinium Pharmaceuticals Radiopharmaceutical Solutions Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Actinium Pharmaceuticals Recent Developments and Future Plans
2.4 Alseres Pharmaceuticals
2.4.1 Alseres Pharmaceuticals Details
2.4.2 Alseres Pharmaceuticals Major Business
2.4.3 Alseres Pharmaceuticals Radiopharmaceutical Solutions Product and Solutions
2.4.4 Alseres Pharmaceuticals Radiopharmaceutical Solutions Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Alseres Pharmaceuticals Recent Developments and Future Plans
2.5 Cardinal Health
2.5.1 Cardinal Health Details
2.5.2 Cardinal Health Major Business
2.5.3 Cardinal Health Radiopharmaceutical Solutions Product and Solutions
2.5.4 Cardinal Health Radiopharmaceutical Solutions Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Cardinal Health Recent Developments and Future Plans
2.6 Jubilant Pharma
2.6.1 Jubilant Pharma Details
2.6.2 Jubilant Pharma Major Business
2.6.3 Jubilant Pharma Radiopharmaceutical Solutions Product and Solutions
2.6.4 Jubilant Pharma Radiopharmaceutical Solutions Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Jubilant Pharma Recent Developments and Future Plans
2.7 Central Research Laboratories
2.7.1 Central Research Laboratories Details
2.7.2 Central Research Laboratories Major Business
2.7.3 Central Research Laboratories Radiopharmaceutical Solutions Product and Solutions
2.7.4 Central Research Laboratories Radiopharmaceutical Solutions Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Central Research Laboratories Recent Developments and Future Plans
2.8 Cyclomedica
2.8.1 Cyclomedica Details
2.8.2 Cyclomedica Major Business
2.8.3 Cyclomedica Radiopharmaceutical Solutions Product and Solutions
2.8.4 Cyclomedica Radiopharmaceutical Solutions Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Cyclomedica Recent Developments and Future Plans
2.9 Bracco
2.9.1 Bracco Details
2.9.2 Bracco Major Business
2.9.3 Bracco Radiopharmaceutical Solutions Product and Solutions
2.9.4 Bracco Radiopharmaceutical Solutions Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Bracco Recent Developments and Future Plans
2.10 Eckert & Ziegler Radiopharma
2.10.1 Eckert & Ziegler Radiopharma Details
2.10.2 Eckert & Ziegler Radiopharma Major Business
2.10.3 Eckert & Ziegler Radiopharma Radiopharmaceutical Solutions Product and Solutions
2.10.4 Eckert & Ziegler Radiopharma Radiopharmaceutical Solutions Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Eckert & Ziegler Radiopharma Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Radiopharmaceutical Solutions Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Radiopharmaceutical Solutions by Company Revenue
3.2.2 Top 3 Radiopharmaceutical Solutions Players 麻豆原创 Share in 2024
3.2.3 Top 6 Radiopharmaceutical Solutions Players 麻豆原创 Share in 2024
3.3 Radiopharmaceutical Solutions 麻豆原创: Overall Company Footprint Analysis
3.3.1 Radiopharmaceutical Solutions 麻豆原创: Region Footprint
3.3.2 Radiopharmaceutical Solutions 麻豆原创: Company Product Type Footprint
3.3.3 Radiopharmaceutical Solutions 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Radiopharmaceutical Solutions Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Radiopharmaceutical Solutions 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Radiopharmaceutical Solutions Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Radiopharmaceutical Solutions 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Radiopharmaceutical Solutions Consumption Value by Type (2020-2031)
6.2 North America Radiopharmaceutical Solutions 麻豆原创 Size by Application (2020-2031)
6.3 North America Radiopharmaceutical Solutions 麻豆原创 Size by Country
6.3.1 North America Radiopharmaceutical Solutions Consumption Value by Country (2020-2031)
6.3.2 United States Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Radiopharmaceutical Solutions Consumption Value by Type (2020-2031)
7.2 Europe Radiopharmaceutical Solutions Consumption Value by Application (2020-2031)
7.3 Europe Radiopharmaceutical Solutions 麻豆原创 Size by Country
7.3.1 Europe Radiopharmaceutical Solutions Consumption Value by Country (2020-2031)
7.3.2 Germany Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Radiopharmaceutical Solutions Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Radiopharmaceutical Solutions Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Radiopharmaceutical Solutions 麻豆原创 Size by Region
8.3.1 Asia-Pacific Radiopharmaceutical Solutions Consumption Value by Region (2020-2031)
8.3.2 China Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Radiopharmaceutical Solutions Consumption Value by Type (2020-2031)
9.2 South America Radiopharmaceutical Solutions Consumption Value by Application (2020-2031)
9.3 South America Radiopharmaceutical Solutions 麻豆原创 Size by Country
9.3.1 South America Radiopharmaceutical Solutions Consumption Value by Country (2020-2031)
9.3.2 Brazil Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Radiopharmaceutical Solutions Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Radiopharmaceutical Solutions Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Radiopharmaceutical Solutions 麻豆原创 Size by Country
10.3.1 Middle East & Africa Radiopharmaceutical Solutions Consumption Value by Country (2020-2031)
10.3.2 Turkey Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Radiopharmaceutical Solutions 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Radiopharmaceutical Solutions 麻豆原创 Drivers
11.2 Radiopharmaceutical Solutions 麻豆原创 Restraints
11.3 Radiopharmaceutical Solutions Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Radiopharmaceutical Solutions Industry Chain
12.2 Radiopharmaceutical Solutions Upstream Analysis
12.3 Radiopharmaceutical Solutions Midstream Analysis
12.4 Radiopharmaceutical Solutions Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

IBA
GE Healthcare
Actinium Pharmaceuticals
Alseres Pharmaceuticals
Cardinal Health
Jubilant Pharma
Central Research Laboratories
Cyclomedica
Bracco
Eckert & Ziegler Radiopharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.